| DR. REDDY'S LABORATORIES, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120130084 | PREPARATION OF FIPAMEZOLE - The application relates to processes for preparing fipamezole and its pharmaceutically acceptable salts, and intermediates thereof. It also provides intermediate compounds of Formula III and Formula IV, and processes for their preparation. | 05-24-2012 |
| 20120101297 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES - Methods of producing compositions of trans-4-amino-2-cyclopentene-1-carboxylic acid derivatives are described. Also described is an amine salt of a compound having formula A, | 04-26-2012 |
| 20120064161 | MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin. | 03-15-2012 |
| 20120046457 | PREPARATION OF DECITABINE - The present application relates to processes for the preparation and purification of decitabine structurally represented by formula (I): | 02-23-2012 |
| 20120045505 | FIXED DOSE DRUG COMBINATION FORMULATIONS - Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets. | 02-23-2012 |
| 20120041029 | COMPOSITIONS FOR DRUG DELIVERY - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 02-16-2012 |
| 20110287097 | PHARMACEUTICAL COMPOSITIONS COMPRISING ROPINIROLE - Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form. | 11-24-2011 |
| 20110275841 | PREPARATION OF DOCETAXEL - The present invention relates to docetaxel and processes for preparing docetaxel, including process-related intermediates. The present invention also relates to processes for preparing substantially pure docetaxel and intermediates. | 11-10-2011 |
| 20110237802 | LENALIDOMIDE SOLVATES AND PROCESSES - The present application relates to lenalidomide salts and solvates, and processes for the preparation thereof. | 09-29-2011 |
| 20110236475 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 09-29-2011 |
| 20110224422 | PREPARATION OF CAPECITABINE - The present invention relates to substantially pure capecitabine and processes for the preparation thereof. | 09-15-2011 |
| 20110218360 | PREPARATION OF RASAGILINE AND SALTS THEREOF - The present invention relates to processes for the preparation of rasagiline mesylate. Also provided is rasagiline mesylate having 90 volume percent of the particles (D | 09-08-2011 |
| 20110213150 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE - Processes for the preparation of palonosetron hydrochloride and its crystalline forms. | 09-01-2011 |
| 20110201800 | AZACITIDINE PROCESS AND POLYMORPHS - Processes for preparing azacitidine. Further included are processes for the preparation of crystalline azacitidine crystalline Form (I) and mixtures of azacitidine crystalline Forms (I) and (II). | 08-18-2011 |
| 20110201631 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED - Pharmaceutical formulations comprising amorphous pemetrexed or its salts, and processes to prepare the formulations. | 08-18-2011 |
| 20110196154 | AMORPHOUS PEMETREXED DISODIUM - Processes for the preparation of amorphous pemetrexed disodium, and removal of residual solvents from amorphous pemetrexed disodium. | 08-11-2011 |
| 20110178470 | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS - Pharmaceutical compositions comprising bortezomib for oral or parenteral administration. Specific aspects relate to stable, sugar free pharmaceutical compositions of bortezomib, including its pharmaceutically acceptable salts or solvates, in the form of ready-to-use solutions, lyophilized forms, or physical admixtures, and the preparation thereof. Other aspects include processes for preparing compositions and methods of using compositions for treating various types of cancers in mammals. | 07-21-2011 |
| 20110177161 | PHARMACEUTICAL COMPOSITIONS OF [5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN - There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2′-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2′-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2′-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. | 07-21-2011 |
| 20110159084 | RALOXIFENE PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations. | 06-30-2011 |
| 20110151258 | PREPARATION OF RANOLAZINE - Preparation of ranolazine and intermediates thereof, for use in pharmaceutical compositions comprising ranolazine. | 06-23-2011 |
| 20110123575 | MODIFIED RELEASE NIACIN FORMULATIONS - Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations. | 05-26-2011 |
| 20110098452 | PURIFICATION OF MODIFIED CYTOKINES - The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition. | 04-28-2011 |
| 20110094321 | PREPARATION OF APREPITANT - A process for preparing aprepitant. | 04-28-2011 |
| 20110086074 | COMBINATIONS OF NIACIN AND AN OXICAM - Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations. | 04-14-2011 |
| 20110064816 | ATORVASTATIN COMPOSITIONS - Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration. | 03-17-2011 |
| 20110040095 | PREPARATION OF MONTELUKAST AND ITS SALTS - Processes for preparing montelukast acid and its salts. | 02-17-2011 |
| 20110028518 | DEXLANSOPRAZOLE PROCESS AND POLYMORPHS - Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation. | 02-03-2011 |
| 20110021567 | PREPARATION OF LENALIDOMIDE - Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide. | 01-27-2011 |
| 20110009362 | SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided. | 01-13-2011 |
| 20100298327 | APREPITANT POLYMORPH MIXTURES - Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific Hweight ratios of the forms. | 11-25-2010 |
| 20100292473 | PROCESS FOR PREPARING (2R,3S/2S,3R)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2- ,4-TRIAZOL-1-YL)BUTAN-2-OL - Voriconazole is prepared by a process comprising condensing 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole-1-yl)ethanone with 4-chloro-6-ethyl-5-fluoropyrimidine, in a ketone, ether, aliphatic hydrocarbon, or aromatic hydrocarbon solvent, to give (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-diflurophenyl)-1-(1H-1,2,4-triazole-1-yl)butan-2-ol. | 11-18-2010 |
| 20100274017 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF - There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same. | 10-28-2010 |
| 20100261908 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS - Processes for the preparation of prasugrel and its pharmaceutically acceptable salts thereof. Also disclosed are polymorphic forms of prasugrel hydrochloride and processes for their preparation. | 10-14-2010 |
| 20100247649 | PHARMACEUTICAL FORMULATIONS COMPRISING TELMISARTAN AND HYDROCHLOROTHIAZIDE - Pharmaceutical tablets comprising a first layer formulated for immediate release of telmisartan from a dissolving matrix and a second layer formulated for immediate release of hydrochlorothiazide from a dissolving matrix, methods for producing tablets and methods of use for treating hypertension. | 09-30-2010 |
| 20100226597 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME - The present application provides a process for the preparation of Bortezomib, its intermediates and process for crystalline forms of Bortezomib. | 09-09-2010 |
| 20100210719 | O-DESMETHYLVENLAFAXINE - Processes for preparing desvenlafaxine and stable amorphous O-desmethylvenlafaxine succinate solid dispersions with one or more pharmaceutically acceptable carriers. | 08-19-2010 |
| 20100197944 | DOCETAXEL PROCESS AND POLYMORPHS - Processes for preparing substantially pure docetaxel, new crystalline forms of docetaxel and processes for preparation thereof, processes for preparing docetaxel trihydrate, and pharmaceutical compositions comprising docetaxel. | 08-05-2010 |
| 20100196464 | ORLISTAT PHARMACEUTICAL FORMULATIONS - Solid pharmaceutical formulations are prepared using compositions comprising orlistat and having average particle sizes less than about 250 μm. | 08-05-2010 |
| 20100160653 | DOCETAXEL POLYMORPHS AND PROCESSES - The present invention provides crystalline polymorphs of docetaxel and processes for preparing them, a method for preparing amorphous docetaxel, and a process for preparing docetaxel. | 06-24-2010 |
| 20100137358 | SOLIFENACIN COMPOSITIONS - Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate. | 06-03-2010 |
| 20100130734 | PROCESS FOR PREPARING CAPECITABINE - There is provided processes for the preparation of capecitabine and intermediates thereof. | 05-27-2010 |
| 20100125149 | IBANDRONATE SODIUM POLYMORPHS - There are provided crystalline forms of Ibandronate sodium and process for preparing thereof. | 05-20-2010 |
| 20100087444 | IMATINIB MESYLATE - There is provided a solid dispersion of imatinib mesylate that includes imatinib mesylate and a pharmaceutically acceptable carrier, wherein said carrier is a cellulose derivative. Also provided is a process for making a solid dispersion and a process for making imatinib. | 04-08-2010 |
| 20100081809 | AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE - The present application relates to amorphous forms of valganciclovir salts such as the hydrochloride and processes for their preparation. | 04-01-2010 |
| 20100069635 | ROSUVASTATIN DEHYDROABIETYLAMINE SALT - There is provided a compound, which is dehydroabietylamine salt of rosuvastatin. Also provided are processes for making rosuvastatin calcium that include formation of dehydroabietylamine salt of rosuvastatin. | 03-18-2010 |
| 20100068269 | TREATMENT AND PREVENTION OF CARDIOVASCULAR EVENTS - A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a β-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering agent; an inhibitor of the renin-angiotensin system; and aspirin. | 03-18-2010 |
| 20100063291 | PROCESS FOR PREPARATION OF SOLID MONTELUKAST - A process for preparation of montelukast or a salt thereof is provided, the process including reacting a late intermediate compound which is 2-[1-[1-R-3-[2-(7 chloro quinolin-2-yl)vinyl [phenyl]-3-[2-methoxy carbonyl phenyl]propyl sulfonyl methyl]cyclo propyl]acetic acid or a salt thereof with methyl magnesium chloride or methyl magnesium bromide in an organic solvent. In one embodiment, the process includes reacting an earlier intermediate compound which is methyl 2-(3-R-(3-(2-(7-chloro 2-quinolinyl)-ethenyl)-3 hydroxy propyl)benzoate with methane sulfonyl chloride or toluene sulfonyl chloride to obtain a mesylated or tosylated derivative of the earlier intermediate compound; followed by a reaction of the mesylated or tosylated derivative with 1-mercapto methyl cyclopropane acetic acid in a polar solvent in a presence of a base to obtain the late intermediate compound. | 03-11-2010 |
| 20100063072 | SOLID FORMS OF PEMETREXED - Duplex coating schemes and associated methods of formation, including a siloxane-based soft coating and a plasma-based SiO | 03-11-2010 |
| 20100029743 | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts. | 02-04-2010 |
| 20100016606 | PREPARATION OF AMORPHOUS HYDROUS ESOMEPRAZOLE MAGNESIUM - A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided. | 01-21-2010 |
| 20090326230 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS - The present invention relates to solifenacin in solid form and a process for its preparation and to a process for the preparation of (1S)-1-Phenyl-1,2,3,4-tetrahydro-isoquinoline, a key intermediate in the synthesis of solifenacin and its salts. | 12-31-2009 |
| 20090252787 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 10-08-2009 |
| 20090247529 | TOPICAL COMPOSITIONS - Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided. | 10-01-2009 |
| 20090209541 | APREPITANT COMPOSITIONS - Pharmaceutical compositions comprising aprepitant, wherein aprepitant solubility in aqueous media is enhanced. | 08-20-2009 |
| 20090137605 | POLYMORPHIC FORMS OF ZIPRASIDONEAND ITS HYDROCHLORIDE SALT AND PROCESS FOR PREPARATION THEREOF - The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and commercially suitable. | 05-28-2009 |
| 20090111776 | Novel tetracycline derivatives as antibacterial agents - In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. | 04-30-2009 |
| 20090099359 | ESZOPICLONE PROCESS - Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride. | 04-16-2009 |
| 20090069557 | PREPARATION OF GEMCITABINE - A process for preparation of gemcitabine hydrochloride and purification thereof. | 03-12-2009 |
| 20090054455 | ARIPIPRAZOLE CO-CRYSTALS - Co-crystals comprising aripiprazole and fumaric acid. | 02-26-2009 |
| 20090047354 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE - The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I) of the present invention is depicted by the following structure. | 02-19-2009 |
| 20090018351 | PREPARATION OF ESCITALOPRAM - The present invention relates to a process for preparing enantiomerically enriched citalopram via methylating enantiomerically enriched didesmethylcitalopram, which is prepared by directly resolving racemic didesmethylcitalopram using a chiral acid. | 01-15-2009 |
| 20080260785 | PAROXETINE COMPOSITIONS - The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered dose. | 10-23-2008 |
| 20080255366 | Crystalline Trihydrate of Zoledronic Acid - Zoledronic acid trihydrate, processes for its preparation, and conversion into zoledronic acid monohydrate. | 10-16-2008 |
| 20080226742 | Compositions for Drug Delivery - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 09-18-2008 |
| 20080214535 | Amorphous Aprepitant Coprecipitates - A coprecipitate comprising amorphous aprepitant and a pharmaceutically acceptable carrier is prepared by rapidly removing solvent from a solution containing aprepitant and the carrier. | 09-04-2008 |
